{"protocolSection":{"identificationModule":{"nctId":"NCT06474806","orgStudyIdInfo":{"id":"64Cu-DOTA-AE105-101"},"secondaryIdInfos":[{"id":"2023-507111-35-00","type":"CTIS"}],"organization":{"fullName":"Curasight","class":"INDUSTRY"},"briefTitle":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","officialTitle":"An Open-label, Two-part, Phase 2 Clinical Trial to Investigate the Safety and Diagnostic Performance of uPAR PET Imaging for Non-invasive Classification of ISUP Grades Among Patients With Localised, Untreated Prostate Cancer.","acronym":"uTRACE-101"},"statusModule":{"statusVerifiedDate":"2024-06","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-06-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2025-09-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2025-09-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-06-06","studyFirstSubmitQcDate":"2024-06-19","studyFirstPostDateStruct":{"date":"2024-06-26","type":"ACTUAL"},"lastUpdateSubmitDate":"2024-06-19","lastUpdatePostDateStruct":{"date":"2024-06-26","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Curasight","class":"INDUSTRY"},"collaborators":[{"name":"ABX CRO","class":"OTHER"}]},"oversightModule":{"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"The goal of this clinical trial is to test if the experimental agent accurately determines the aggressiveness of prostate cancer (biopsy-verified ISUP grade). The aim is that the diagnostic PET imaging agent may be used as an alternative or supplement to biopsies in the monitoring of patients with low-risk prostate cancer in active surveillance.\n\nPatients diagnosed with untreated, low-grade, localized prostate cancer may participate in the trial. The experimental diagnostic agent 64Cu-DOTA-AE105 is a radiopharmaceutical which is injected into the veins and binds to uPAR expressing cells in the tumour which can then be visualized in a PET scanner.\n\nThe main question the trial aims to answer is: Can the test drug be used alone or as a supplement to repeated biopsies to accurately assess the aggressiveness of prostate cancer?\n\nThe trial is divided in 2 parts:\n\n* Participants in the first part will receive 2 injections of test drug on 2 different days.\n\n  * The first day the participant will receive an injection of the test drug and then be asked to lie down in the PET/CT scanner so that images of the prostate can be taken. Before and after the injection/scanning procedure the participant will have tests done. These tests will include evaluation of health status, measurement of heart function by ECG plus blood and urine samples.\n  * After 8 days the procedures, including injection of test drug and scanning, will be repeated.\n* Participants in the second part of the trial will only have 1 injection of the test drug and subsequent PET/CT scanning. Like in Part 1 of the trial, tests will be done before and after the injection/ scanning procedure."},"conditionsModule":{"conditions":["Prostate Cancer"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","interventionModelDescription":"The trial consist on 2 parts: Part 1 will evaluate 3 different doses of 64Cu-DOTA-AE105 in parallel (100, 150, or 200 MBq) in 27 patients (randomized 1:1:1) . Part 2 will evaluate 1 dose of 64Cu-DOTA-AE105 (200 MBq) in 141 patients","primaryPurpose":"DIAGNOSTIC","maskingInfo":{"masking":"NONE"}},"enrollmentInfo":{"count":168,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"100 MBq 64Cu-DOTA-AE105","type":"EXPERIMENTAL","description":"For Part 1 of the trial, 9 patients will receive 100 MBq 64Cu-DOTA-AE105 Day 1 and Day 8","interventionNames":["Drug: 64Cu-DOTA-AE105"]},{"label":"150 MBq 64Cu-DOTA-AE105","type":"EXPERIMENTAL","description":"For Part 1 of the trial, 9 patients will receive 150 MBq 64Cu-DOTA-AE105 Day 1 and Day 8","interventionNames":["Drug: 64Cu-DOTA-AE105"]},{"label":"200 MBq 64Cu-DOTA-AE105","type":"EXPERIMENTAL","description":"For Part 1 of the trial, 9 patients will receive 200 MBq 64Cu-DOTA-AE105 Day 1 and Day 8.\n\nFor Part 2 of the trial, additional 141 patients will receive 200 Mbq 64Cu-DOTA-AE105","interventionNames":["Drug: 64Cu-DOTA-AE105"]}],"interventions":[{"type":"DRUG","name":"64Cu-DOTA-AE105","description":"AE105 is a uPAR-specific peptide that is bound to the chelator DOTA, which in turn holds the diagnostic radionuclide copper-64 (64Cu), which can be detected upon decay by PET imaging.","armGroupLabels":["100 MBq 64Cu-DOTA-AE105","150 MBq 64Cu-DOTA-AE105","200 MBq 64Cu-DOTA-AE105"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Part 1: Standard uptake value (SUV) max at 30, 60, and 120 minutes post-injection (p.i.) - robustness","description":"Part 1: mean of 3 independent readings of SUVmax at positron emission tomography (PET) aquisition times 30, 60, and 120 minutes p.1","timeFrame":"Day 1"},{"measure":"Part 2: SUVmax at 60 minutes p.i.","description":"Part 2: mean of 3 independent readings of SUVmax at PET aquisition time 60 minutes p.i.","timeFrame":"60 minutes post-injection"}],"secondaryOutcomes":[{"measure":"Part 1: SUVmax in PET acquisitions at 60 minutes p.i.","description":"Part 1: mean of 3 independent readings of SUVmax at PET aquisition time 60 minutes Day 1 and Day 8","timeFrame":"Day 1 and Day 8"},{"measure":"Part 1: Cmax from periodic radioactive counts from whole blood","description":"Cmax from periodic radioactive counts from whole blood based on pre-injection and 5 post-injection samples","timeFrame":"Day 1"},{"measure":"Part 1:Tmax from periodic radioactive counts from whole blood","description":"Part 1: Tmax from periodic radioactive counts from whole blood based on pre-injection and 5 post-injection samples","timeFrame":"Day 1"},{"measure":"Part 1: Area under curve (AUC) from periodic radioactive counts from whole blood","description":"AUC from periodic radioactive counts from whole blood based on pre-injection and 5 post-injection samples","timeFrame":"Day 1"},{"measure":"Part 1:Volume of distribution (Vd) from periodic radioactive counts from whole blood","description":"Part 1: Vd from periodic radioactive counts from whole blood based on pre-injection and 5 post-injection samples","timeFrame":"Day 1"},{"measure":"Part 1:Clearance from periodic radioactive counts from whole blood","description":"Part 1: Clearance from periodic radioactive counts from whole blood based on pre-injection and 5 post-injection samples","timeFrame":"Day 1"},{"measure":"Part 1: Elimination of 64Cu-DOTA-AE105 into a pooled urine sample","description":"Part 1: Activity (MBq) per mL in urine samples pooled for the 3 hours following injection","timeFrame":"Day 1"},{"measure":"Part 1: Inter-reader variability of SUVmax","description":"Part 1: Variability of 3 independent SUVmax readings at 30, 60, and 120-minutes p.i.","timeFrame":"Day 1"},{"measure":"Part 1:Intra-reader variability of SUVmax","description":"Part 1: Variability of SUVmax readings at 30, 60, and 120-minutes p.i.","timeFrame":"Day 1"},{"measure":"Part 1: Inter-reader variation in tumour visibility","description":"Part 1: Tumor visibility in PET acquisitions evaluated by individual readings (numerical rating scale \\[NRS\\], 0-2 rating) at 30, 60, and 120 min p.i.","timeFrame":"Day 1"},{"measure":"Part 1: Intra-reader variation in tumour visibility","description":"Part 1: Tumor visibility in PET acquisitions evaluated by individual readings (numerical rating scale \\[NRS\\], 0-2 rating) at 30, 60, and 120 min p.i.","timeFrame":"Day 1"},{"measure":"Part 1: SUVmax using different acquisition durations","description":"Part 1: mean of 3 independent readings of SUVmax centered around 60 minutes p.i. in frame durations of 3-, 5-, 10-, 20-, 30-, and 40-minutes","timeFrame":"Day 1"},{"measure":"Part 1: Variation in tumour visibility using different acquisition durations in the 200 MBq cohort","description":"Part 1: median of 3 central readings of tumor visibility (NRS, 0-2 rating), centered around 60 minutes p.i. in frame durations of 3-, 5-, 10-, 20-, 30-, and 40-minutes","timeFrame":"Day 1"},{"measure":"Part 2: SUVmax variation between local and central readers","description":"Part 2: mean of 3 central readers and read of 1 local reader of SUVmax in PET acquisitions at 60 minutes p.i.","timeFrame":"60 minutes post-injection"},{"measure":"Part 2: Tumour visibility in PET acquisitions","description":"Part 2: median of 3 central readings of tumor visibility (NRS, 0-2 rating) and read of 1 local reader in PET acquisitions at 60 minutes p.i.","timeFrame":"60 minutes post injection"},{"measure":"Part 2: Intra-reader variability of SUVmax","description":"Part 2: Variability of SUVmax readings at 60-minutes p.i.","timeFrame":"60 minutes post injection"},{"measure":"Part 2: Inter-reader variability of SUVmax","description":"Part 2: Variability of 3 independent SUVmax readings at 60 minutes p.i.","timeFrame":"60 minutes post injection"},{"measure":"Part 2: Inter-reader tumour visibility in PET acquisitions","description":"Part 2: individual readings by 3 central readers and 1 local reader of tumor visibility (NRS, 0-2 rating) in PET acquisitions at 60 minutes p.i.","timeFrame":"60 minutes post injection"},{"measure":"Part 2: Intra-reader tumour visibility in PET acquisitions","description":"Part 2: individual readings by 3 central readers and 1 local reader of tumor visibility (NRS, 0-2 rating) in PET acquisitions at 60 minutes p.i.","timeFrame":"60 minutes post injection"}],"otherOutcomes":[{"measure":"Incidence of adverse events","description":"Part 2: Adverse events (AEs) will be assessed and graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 5.0","timeFrame":"Day 3"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Pathology-verified prostate adenocarcinoma\n* International Society of Urological Pathology (ISUP) grade 1 to 3\n* Localised prostate cancer (N0 and M0 status) (only required for ISUP 3 patients)\n\n  1. Newly diagnosed patients: Staging must be performed within 6 months from enrolment into the trial.\n  2. Active surveillance: N0/M0 at the time of diagnosis and no clinical suspicion of prostate cancer outside the prostatic bed at the time of enrolment into the trial.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-2\n* Prostate biopsy within 1 to 6 months (patients with a biopsy within the last month are excluded to avoid possible inflammation artefacts on the PET scan)\n\n  1. The biopsy can be part of the primary staging, a confirmatory biopsy, or serial biopsy as part of an AS.\n  2. At least 1 core must be MRI-guided.\n\nExclusion Criteria:\n\n* Any prior treatment for prostate cancer (surgery, external beam radiation therapy, brachytherapy, hormone therapy, or chemotherapy)\n* Chronic prostatitis (any signs or symptoms of chronic bacterial prostatitis or chronic pelvic prostatitis and pain syndrome, or known diagnosis of asymptomatic inflammatory prostatitis)\n* Acute infections within the prostatic bed or lower urinary tract infections\n* Participants have inadequate bone marrow, kidney, liver, heart, or lung function:","healthyVolunteers":false,"sex":"MALE","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Project Manager","role":"CONTACT","phone":"+45 22830160","email":"info@curasight.com"}],"overallOfficials":[{"name":"Andreas Kj√¶r","affiliation":"Curasight","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Aalborg University Hospital","status":"RECRUITING","city":"Aalborg","country":"Denmark","contacts":[{"name":"Prof. Zacho, MD,","role":"CONTACT","email":"hzacho@dcm.aau.dk"}],"geoPoint":{"lat":57.048,"lon":9.9187}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-07-01"},"conditionBrowseModule":{"meshes":[{"id":"D000011471","term":"Prostatic Neoplasms"}],"ancestors":[{"id":"D000005834","term":"Genital Neoplasms, Male"},{"id":"D000014565","term":"Urogenital Neoplasms"},{"id":"D000009371","term":"Neoplasms by Site"},{"id":"D000009369","term":"Neoplasms"},{"id":"D000005832","term":"Genital Diseases, Male"},{"id":"D000091662","term":"Genital Diseases"},{"id":"D000091642","term":"Urogenital Diseases"},{"id":"D000011469","term":"Prostatic Diseases"},{"id":"D000052801","term":"Male Urogenital Diseases"}],"browseLeaves":[{"id":"M14335","name":"Prostatic Neoplasms","asFound":"Prostate Cancer","relevance":"HIGH"},{"id":"M8946","name":"Genital Neoplasms, Male","relevance":"LOW"},{"id":"M17315","name":"Urogenital Neoplasms","relevance":"LOW"},{"id":"M2876","name":"Genital Diseases","relevance":"LOW"},{"id":"M8944","name":"Genital Diseases, Male","relevance":"LOW"},{"id":"M2875","name":"Urogenital Diseases","relevance":"LOW"},{"id":"M14333","name":"Prostatic Diseases","relevance":"LOW"},{"id":"M27095","name":"Male Urogenital Diseases","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC04","name":"Neoplasms"},{"abbrev":"BXS","name":"Urinary Tract, Sexual Organs, and Pregnancy Conditions"},{"abbrev":"All","name":"All Conditions"}]},"interventionBrowseModule":{"browseLeaves":[{"id":"M5860","name":"Chelating Agents","relevance":"LOW"},{"id":"M6523","name":"Copper","relevance":"LOW"},{"id":"T338","name":"Copper Supplement","relevance":"LOW"}],"browseBranches":[{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Micro","name":"Micronutrients"},{"abbrev":"Mi","name":"Mineral"}]}},"hasResults":false}